Taro Pharmaceutical Industries Ltd.

NYSE:TARO Rapport sur les actions

Capitalisation boursière : US$1.6b

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Taro Pharmaceutical Industries Bilan de santé

Santé financière contrôle des critères 6/6

Taro Pharmaceutical Industries has a total shareholder equity of $1.8B and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $2.2B and $369.1M respectively. Taro Pharmaceutical Industries's EBIT is $7.3M making its interest coverage ratio -0.1. It has cash and short-term investments of $879.4M.

Informations clés

0%

Ratio d'endettement

US$0

Dette

Ratio de couverture des intérêts-0.1x
Argent liquideUS$879.35m
Fonds propresUS$1.79b
Total du passifUS$369.06m
Total des actifsUS$2.16b

Mises à jour récentes de la santé financière

Recent updates

Taro Pharmaceutical Industries Ltd. Is An Overlooked Opportunity

Dec 12

Taro Pharmaceutical: Sun Pharma Deal Uncertain, No Discernible Value Beyond NAV (Rating Downgrade)

Aug 16

Taro Pharmaceutical: Potential Value In Sun Pharma Offer

Jun 02

Taro Pharmaceutical: Stagnating Growth At 1.6% Trailing Earnings Yield, Rate Hold

Feb 24

Taro Pharmaceutical GAAP EPS of $0.19 misses by $0.68, revenue of $139.2M misses by $23.92M

Jan 24

Taro Pharmaceutical Non-GAAP EPS of $0.66 misses by $0.18, revenue of $130.5M misses by $30.52M

Oct 28

Taro Pharmaceutical hits 52-week low; down 28% YTD

Aug 15

Taro Pharmaceutical Non-GAAP EPS of $1.09 beats by $0.24, revenue of $156.7M beats by $6.8M

Jul 27

Taro Pharmaceutical: 10%+ Projected Earnings Yield Is A Strong Calling Card

Jul 14

We Think Taro Pharmaceutical Industries' (NYSE:TARO) Healthy Earnings Might Be Conservative

Aug 03
We Think Taro Pharmaceutical Industries' (NYSE:TARO) Healthy Earnings Might Be Conservative

A Look At Taro Pharmaceutical Industries' (NYSE:TARO) Share Price Returns

Jan 26
A Look At Taro Pharmaceutical Industries' (NYSE:TARO) Share Price Returns

Analyse de la situation financière

Passif à court terme: TARO's short term assets ($1.3B) exceed its short term liabilities ($361.1M).

Passif à long terme: TARO's short term assets ($1.3B) exceed its long term liabilities ($8.0M).


Historique et analyse du ratio d'endettement

Niveau d'endettement: TARO is debt free.

Réduire la dette: TARO had no debt 5 years ago.

Couverture de la dette: TARO has no debt, therefore it does not need to be covered by operating cash flow.

Couverture des intérêts: TARO has no debt, therefore coverage of interest payments is not a concern.


Bilan


Découvrir des entreprises saines